Randox Adiponectin Assay Gains CE Approval
World-leading diagnostics firm Randox Laboratories has recently launched a biochemistry Adiponectin assay. Testing adiponectin allows assessment of the risk of developing Type 2 diabetes and Cardiovascular Disease (CVD). In using Latex-Enhanced Immunoturbidimetric technology, Randox have brought a superior option for Adiponectin assessment to the clinical diagnostics market.
Adiponectin is a protein hormone produced and secreted exclusively by adipocytes. It regulates the metabolism of lipids and glucose, and influences the body's response to insulin. Adiponectin also has anti-inflammatory effects on the cells lining the walls of blood vessels. Low levels of Adiponectin therefore can be indicative of insulin resistance (leading to type 2 diabetes), and Cardiovascular Disease (CVD). Low adiponectin levels have also been shown to correlate with increased likelihood of a woman developing gestational diabetes in pregnancy.
Randox also offers 2 levels of adiponectin controls as well as an adiponectin calibrator, delivering a complete testing package.
Speaking after the approval announcement, Randox Managing Director Dr Peter FitzGerald said,
“It is clear that in the 21st Century, increasing sedentary and deskbound lifestyles are driving chronic conditions such as diabetes and cardiovascular disease. 382 million people currently live with diabetes across the world and according to the International Diabetes Federation, this figure is predicted to rise by 55% by 2015. Adiponectin assesses an individual’s risk of developing diabetes, and allows resources and treatment to be focused on those patients most at risk. This highly targeted strategy should help to decrease the number of people becoming diabetic, while using resources most effectively.”